liver and semaglutide Gets FDA Greenlight for MASH Semaglutide Shows Promise for Treating

Employers that prioritize cardiometabolic health as a business strategy will find that GLP-1s are just one piece though potentially a key piece of a larger puzzle.

Sign up to receive Medicare news, policy developments, and other useful updates from the Medicare Rights

doi: 10.1371/journal.pcbi.1002687 40 LiuP-Y

The other challenge is making sure patients have access to healthcare providers who are comfortable having real conversations about obesity and can guide people through the long-term lifestyle changes that are needed

The scale may move slowly, but measurements continue improving as body recomposes

Painting and drawing are big creative outlets for me